Cannabis Technologies Inc.

Cannabis Technologies Inc.

September 09, 2014 09:00 ET

Cannabis Technologies Appoints Dr. Peter Huang as Senior Bioinformatician

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 9, 2014) - Cannabis Technologies Inc. (the Company) (CSE:CAN)(OTCQB:CANLF) announces today that Peter Huang has been appointed the Senior Bioinformatician for Cannabis Technologies. Mr. Huang has more than 17 years of experience as a Bioinformatician, software developer, and biological researcher.

"We are pleased to welcome Peter as our Senior Bioinformatician to the Company," said Dr. Sazzad Hossain, Chief Scientific Officer. Mr. Huangs's expertise will focus on the biological information management of our proprietary Platform Technology. His efforts will be focused on rapidly enabling the Company to discover novel cannabis based drug therapies to add to our growing therapy pipeline.

Mr. Huang's experience spans multiple disciplines within computer and biological sciences. Mr. Huang has successfully piloted various projects including plant mutation discoveries as well as developed various biological information management systems for several laboratories. Mr. Huang has extensive experience and knowledge in software development, database management and computer system administration. He has helped install and manage computer clusters for high performance distributed computing in order to improve biological data analysis capabilities. Due to Mr. Huang's success in identifying novel genes in the C. elegans genome in 2004, he was invited by Dr. Richard Durbin, Acting Head of Computational Genomics at the Wellcome Trust Sanger Institute and leader of the Genome Informatics group to visit the Sanger Institute in the UK for a collaboration.

Mr. Huang was recently with the Vineland Research and Innovation Center as a Senior Bioinformatician and previously with US Genomics in Massachusetts, USA as a Bioinformatics Scientist.

Mr. Huang received a Master of Science in Botany and Microbiology with Auburn University (1995) and a B.S. degree in Computer Science from Simon Fraser University in BC, Canada (1999).

About Cannabis Technologies ("CTI")

CTI is a biopharmaceutical drug discovery and development company uniquely focused on the pharmacology and therapeutic potential of cannabinoids.

CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain genes responsible for specific diseases.

Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ocular, Cancer & Angiogenesis, and Inflammation, Pain.


Craig Schneider, President and CEO

For further information, please visit the company's website at

Forward-Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause Cannabis Technologies actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and Cannabis Technologies disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.


Contact Information